Navigate the path from discovery to medicine 

Plan, manage, and execute R&D programs with Orchestra

Clear alignment between cross-functional teams

Align trade-offs with resource constraints

Understand how program changes impact your entire portfolio

Efficacy studies

IND filing

Backup GMP production

In vivo GLP studies

Cell line development

Assay development

$3M and 18w

Safety/toxicity studies

Process development

Antibody optimization

GMP production

Navigate program complexity

Map critical dependencies across teams

Set portfolio strategy

Balance risk and opportunity across your pipeline

ORC-001

Oncology

Discovery

Preclinical

Clinical

Regulatory

Accelerate IND timeline

ORC-002

Autoimmune

Discovery

Preclinical

Clinical

Regulatory

Initiate backup to derisk ORC-002

ORC-002

Metabolic

Discovery

Preclinical

Clinical

Regulatory

Partner milestones at risk

ORC-001

Oncology

Accelerate IND timeline

ORC-002

Autoimmune

Initiate backup to derisk ORC-002

ORC-002

Metabolic

Partner milestones at risk

Portfolio decisions

Tara · CEO

What can we do to make sure ORC-002 is ready for Phase 1 trials next year?

Tara · CEO

What can we do to make sure ORC-002 is ready for Phase 1 trials next year?

Overview and scenarios

Ashoka · Program Manager

Would we reach IND faster if we ran in vivo efficacy studies in parallel to our backup screens?

Ashoka · Program Manager

Would we reach IND faster if we ran in vivo efficacy studies in parallel to our backup screens?

Timelines and resources

Trey · CMC Lead

Can we ramp up production so that we can increase trial enrollment?

Trey · CMC Lead

Can we ramp up production so that we can increase trial enrollment?

Study readouts

Ky · Scientist

If this run is late, what are the downstream impacts? Should we change the plan to finish on time?

Ky · Scientist

If this run is late, what are the downstream impacts? Should we change the plan to finish on time?

Experiments and data

Deliver from bench to boardroom

Connect strategy to execution

Navigate program complexity

Map critical dependencies across teams

Clear alignment between cross-functional teams

Align trade-offs with resource constraints

Understand how program changes impact your entire portfolio

Efficacy studies

IND filing

Backup GMP production

In vivo GLP studies

Cell line development

Assay development

$3M and 18w

Safety/toxicity studies

Process development

Antibody optimization

GMP production

Deliver from bench to boardroom

Connect strategy to execution

Tara · CEO

What can we do to make sure ORC-002 is ready for Phase 1 trials next year?

Ashoka · Program Manager

Would we reach IND faster if we ran in vivo efficacy studies in parallel to our backup screens?

Trey · CMC Lead

Can we ramp up production so that we can increase trial enrollment?

Ky · Scientist

If this run is late, what are the downstream impacts? Should we adjust?

Portfolio decisions

Overview and scenarios

Study readouts

Timelines and resources

Experiments and data

See Orchestra in action

Strategic planning, operations, and scenario management all in one platform

Ready to get started?

Ready to get started?

Get a personalized demo of Orchestra in action to learn how we can help your organization plan, manage, and execute complex programs.

© 2024 Orchestra Bio, Inc.

hello@orchestra.bio

Ready to get started?

Get a personalized demo of Orchestra in action to learn how we can help your organization plan, manage, and execute complex programs.

© 2024 Orchestra Bio, Inc.

hello@orchestra.bio